Other
LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules
LIR Life Sciences Advances Transdermal Platform Amidst Stock Decline; No Clinical Catalysts Yet
Executive Summary
- Most Recent Update (April 28, 2026): LIR Life Sciences launched an ex vivo porcine skin study to evaluate protamine-enhanced transdermal transport of larger therapeutic molecules (5 kDa to ~150 kDa). This confirms execution of a study design finalized in January 2026.
- Collaboration (April 20, 2026): Entered a Technology Development Collaboration Agreement with Resilience BioSciences Inc. for early-stage experimental work at UBC facilities ($5,000/month).
- R&D Progression: Follows Phase 2 peptide design activities with Neuland Laboratories (February 2026) and positive interim preclinical results from GLP/GIP-based therapy studies in January 2026.
- Corporate Structure: Completed acquisition of LIR Life Sciences Inc. by Blackbird Critical Metals Corp. in November 2025, changing name to LIR Life Sciences Corp., with concurrent financing and debt conversion.
Material Impact
- Catalyst Status: The April 28 news confirms the execution of a planned study but does not provide new data or results. It is an incremental step in R&D rather than a breakthrough milestone.
- Market Expectation: Given the stock's decline from $2.35 (January peak) to $0.48, the market has likely priced out near-term optimism following the January interim results announcement. This news does not alter that sentiment significantly as it offers no new positive data points.
- Financial Impact: The collaboration costs ($5k/month) are immaterial relative to the company's cash position but indicate ongoing operational burn.
- Risk Profile: The focus on larger molecules (up to 150 kDa, antibody scale) introduces higher scientific risk compared to smaller peptides, as transdermal delivery of macromolecules is technically challenging and less proven.
SKNY · Price
Company Overview
- Company: LIR Life Sciences Corp. (formerly Blackbird Critical Metals Corp.). Ticker: SKNY (CSE).
- Flagship Project: Transdermal delivery platform using Cell-Penetrating Peptides (CPP) and Protamine to enable needle-free administration of GLP/GIP-based obesity therapies and larger macromolecules.
- Development Stage: Preclinical. Animal studies completed in mice; ex vivo porcine skin studies underway. No human clinical trials initiated as of April 2026.
- Technology: Focuses on enhancing skin permeability for therapeutic molecules ranging from small peptides to antibody-scale proteins (150 kDa).
More from LIR Life Sciences Corp.
Jun 17, 2026 · 18:00